Arsenic trioxide

Generic Name: Arsenic trioxide

Brand Names: Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac

Drug Type: Small Molecule

Chemical Formula: As_₂O_₃

CAS Number: 1327-53-3

Unique Ingredient Identifier: S7V92P67HO

Background: Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.

Indication: For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression

Associated Conditions: Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia

Clinical Trials

Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia

Phase 3

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Promyelocytic Leukemia (M3)
Childhood Acute Promyelocytic Leukemia (M3)
Untreated Adult Acute Myeloid Leukemia
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Interventions: Drug: tretinoin
Drug: daunorubicin hydrochloride
Drug: cytarabine
Drug: arsenic trioxide
Drug: mercaptopurine
Drug: methotrexate

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 420

Registration Number: NCT00003934

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Arsenic Trioxide

First Posted Date: 2003-01-27

Last Posted Date: 2012-09-26

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 2

Registration Number: NCT00006092

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: arsenic trioxide

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 13

Registration Number: NCT00008697

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: arsenic trioxide
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00045565

Locations: 🇺🇸
New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States

Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-15

Lead Sponsor: University of Miami

Target Recruit Count: 22

Registration Number: NCT00006021

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸
Baptist-South Miami Regional Cancer Program, Miami, Florida, United States

and more 1 locations

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

Phase 2

Completed

Conditions: Extragonadal Germ Cell Tumor
Kidney Cancer
Ovarian Cancer
Retinoblastoma
Brain and Central Nervous System Tumors
Childhood Germ Cell Tumor
Liver Cancer
Neuroblastoma
Sarcoma

Interventions: Drug: arsenic trioxide

First Posted Date: 2003-01-27

Last Posted Date: 2015-11-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT00024258

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2018-08-17

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 37

Registration Number: NCT00004149

Locations: 🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇺🇸
Mount Sinai Medical Center, NY, New York, New York, United States
🇺🇸
Albert Einstein Clinical Cancer Center, Bronx, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy